REVIEW article
Front. Endocrinol.
Sec. Thyroid Endocrinology
This article is part of the Research TopicLiquid Biopsy in Diagnosis and Treatment of Thyroid CancerView all articles
Emerging Liquid Biopsy Markers in Thyroid Cancer: From Isolation Technologies to Clinical Translation
Provisionally accepted
- First Hospital of Shanxi Medical University, Taiyuan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Diagnosis and treatment of thyroid cancer (TC) are undergoing radical changes, shifting from traditional tissue studies to liquid biopsies (LB). LB technologies provide effective, non-invasive solutions to these challenges. This paper reviews recent advances in the analysis of three important biomarker systems: circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and exosomes. Technically, microfluidics and bioaffinity-based physical capture strategies have significantly improved the efficiency with which CTCs can be separated and analysed at an individual cell level. Ultra-sensitive digital polymerase chain reaction (dPCR) and targeted sequencing enable accurate characterisation of rare mutations and methylation alterations in ctDNA. Additionally, innovations in ultracentrifugation and new microfluidic chips have improved the efficiency with which exosomes and the information molecules they contain (e.g., miRNA and lncRNA) are extracted and detected. These abundant liquid biomarkers demonstrate significant value in clinical translation. CTCs provide a unique opportunity to study the mechanisms of metastasis and tumor heterogeneity, while ctDNA plays a central role in preoperative risk classification, monitoring minimal residual disease and tracking the dynamics of drug-resistant mutations. Exosomes, as stable carriers of nucleic acids, have significant potential for early diagnosis and assessment of treatment efficacy. Nevertheless, this field still faces significant challenges, including a lack of technical standardisation and integration of different biomarker results, insufficient sensitivity in patients with low tumor burden and a lack of broad preclinical validation. In the future, joint analysis of multigenomic biomarkers and deep integration of the latest technologies, such as microfluidics and artificial intelligence, promise to create a more comprehensive ecosystem for precise TC diagnosis and treatment.
Keywords: Circulating Tumor Cells (CTCs), circulating tumor DNA (ctDNA), Exosomes, liquid biopsies (LB), Thyroid cancer (TC)
Received: 30 Nov 2025; Accepted: 26 Jan 2026.
Copyright: © 2026 Gao, Li, Wei, Duan, Hou, Fu, Wang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Huiling Li
Ling Li
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.